Compare Coupang Inc (CPNG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs BIO-TECHNE Corp — how do they compare? Coupang Inc trades at $15.75 (market cap $27.70B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: Coupang Inc is far larger — about 2.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Coupang Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and BIO-TECHNE Corp for 63 Days on average.
| CPNG | TECH | |
|---|---|---|
Market Cap | $27.70B | $11.36B |
Volume | 27,703,608 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.47 | $72.61 |
52-Week Low | $13.75 | $43.31 |
Typical Hold Time | 55 Days | 63 Days |
Enterprise Value | $27.22B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPNG trades at $14.81, up 2.7% today, with a bullish technical signal despite recent earnings misses. The company shows strong revenue growth to $34.53B in 2025 but faces profitability challenges with a negative net margin of -2.16%. Analyst sentiment remains overwhelmingly positive with 87.5% buy ratings and a $25.25 consensus price target, representing 70% upside potential.
The stock offers significant upside based on analyst targets but carries execution risks amid competitive pressures and inconsistent profitability. Recent earnings misses and negative ROE of -19.99% highlight operational challenges, while strong cash flow generation and market dominance in South Korea provide fundamental support for long-term growth.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
